Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer (Q34813272)

4 August 2017

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer (English)

1 reference

4 August 2017

24

1 reference

Frédérique Penault-Llorca

4 August 2017

21

Frédérique Penault-Llorca

0 references

Nicola Aceto

Nicola Aceto

Nerissa Therese Viola-Villegas

6

0 references

Nerissa Therese Viola-Villegas

12

0 references

Pau Castel

Pau Castel

2

0 references

Borivoj Vojnovic

Borivoj Vojnovic

9

0 references

Tony Ng

Tony Ng

20

0 references

Paul R Barber

Paul Barber

8

1 reference

ORCID Public Data File 2021

Shyamala Maheswaran

19

Shyamala Maheswaran

1 reference

4 August 2017

Jessica J Tao

1

1 reference

4 August 2017

Nina Radosevic-Robin

3

1 reference

4 August 2017

Moshe Elkabets

4

1 reference

4 August 2017

Neil Auricchio

5

1 reference

4 August 2017

Gregory Weitsman

7

1 reference

4 August 2017

Haley Ellis

10

1 reference

4 August 2017

Natasha Morse

11

1 reference

4 August 2017

Ana Bosch

13

1 reference

4 August 2017

Dejan Juric

14

1 reference

4 August 2017

Saswati Hazra

15

1 reference

4 August 2017

Sharat Singh

16

1 reference

4 August 2017

Phillip Kim

17

1 reference

4 August 2017

Anna Bergamaschi

18

1 reference

4 August 2017

Jason S Lewis

22

1 reference

4 August 2017

Lisa A Carey

23

1 reference

4 August 2017

José Baselga

25

1 reference

4 August 2017

Maurizio Scaltriti

26

1 reference

4 August 2017

25 March 2014

1 reference

4 August 2017

1 reference

4 August 2017

7

1 reference

4 August 2017

318

1 reference

4 August 2017

ra29

1 reference

Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

The Gray Institute 'open' high-content, fluorescence lifetime microscopes.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Neoadjuvant treatments for triple-negative breast cancer (TNBC).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Triple-Negative Breast Cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Triple-negative breast cancer: disease entity or title of convenience?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Kinase-mediated quasi-dimers of EGFR

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Standardized methods for the production of high specific-activity zirconium-89.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Inhibitor hijacking of Akt activation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Intracellular coupling of adhesion receptors: molecular proximity measurements

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Imaging protein kinase Calpha activation in cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Pattern of metastatic spread in triple-negative breast cancer

8 July 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005125

Directed therapy of subtypes of triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005125

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005125

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005125

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005125

A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005125

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283215

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24667376

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1126/SCISIGNAL.2005125

1 reference

release_7e5tftvtpjar5gpuoxtnbvd6cy

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7e5tftvtpjar5gpuoxtnbvd6cy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMCID

4283215

1 reference

4 August 2017

1 reference